Clinical Scorecard: Naive-Like T Cells Linked to CAR T Durability

At a Glance

Key Highlights

• In a multicenter analysis of 580 axi-cel-treated patients, higher naive-like T cell proportions in the product were associated with longer progression-free survival.
• The highest-proportion group had a 54% lower relative hazard of progression or death than the lowest-proportion group; ongoing response rates were 59.3% versus 29.2%.
• The association remained significant after accounting for tumor burden, systemic inflammation, and CAR T cell expansion; tumor microenvironment characteristics were assessed in a 112-patient subset.
• Findings were validated in an independent cohort of 203 patients; a separate analysis of 116 patients linked a naive-like, low-exhaustion-marker CD8 T cell population with longer progression-free survival.
• More prior treatment lines were associated with fewer naive-like T cells in starting material and final products; the study establishes association, not causation.

Guideline-Based Recommendations

Diagnosis

Management

• The source states that manufacturing strategies designed to preserve or enrich less-differentiated T cells could help improve treatment durability, but further studies are needed to determine whether modifying product composition directly improves outcomes.

Monitoring & Follow-up

Risks

• No increase in cytokine release syndrome or neurotoxicity severity was observed in the group with the highest naive-like T cell proportions.
• The source notes that findings may not extend to all CAR T platforms; the analysis focused on CD28-based products in patients with lymphoma.

Patient & Prescribing Data

The primary analysis included 580 patients with non-Hodgkin lymphoma treated with axi-cel across multiple clinical trials, with median follow-up of 41.9 months. Validation included 203 patients treated with axi-cel-based therapies or brexucabtagene autoleucel.

Higher proportions of naive-like T cells in the final CAR T cell product were associated with longer progression-free survival and higher ongoing response rates. Product composition was more strongly associated with outcomes than naive-like cell proportions in starting material.

Clinical Best Practices

• The study reports associations between naive-like T cell proportions and outcomes, not causation.
• The analysis focused on CD28-based CAR T products in patients with lymphoma.
• The source states that further studies are needed to determine whether modifying product composition directly improves clinical outcomes.

Related Resources & Content